Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
GI Cancers Symposium
Gene-Expression Profiling May Help Select Best Drugs for Pancreatic Cancer
By
Caroline Helwick
GI Cancers Symposium
February 2013, Vol 4, No 2
San Francisco, CA—Gene-expression profiling (GEP) of circulating tumor cells (CTCs) may help to personalize chemotherapy for patients with pancreatic cancer by predicting how patients will respond to certain treatments, according to a study reported at the 2013 Gastrointestinal Cancers Symposium.
Read Article
Mayo Clinic Researchers Propose Screening Algorithm for HER2 in Patients with Esophageal Cancer
By
Caroline Helwick
GI Cancers Symposium
February 2013, Vol 4, No 2
The preferred screening test for human epidermal growth factor receptor (HER)2 status in surgical esophageal adenocarcinoma specimens is immunohistochemistry (IHC), with fluorescence in situ hybridization (FISH) restricted to cases with an indeterminate (2+) IHC score, according to investigators from the Mayo Clinic, Rochester, MN, who proposed a testing algorithm at the 2013 Gastrointestinal Cancers Symposium.
Read Article
In Patients with Colon Cancer, Genomic Classifiers Aid in Prognosis
By
Caroline Helwick
GI Cancers Symposium
February 2013, Vol 4, No 2
San Francisco, CA—Genomic classifiers—in particular, ColoPrint and MSI-Print, best when combined—can identify high-risk subsets among patients with surgically resected stage II and stage III colon cancers, reported researchers from M.D. Anderson Cancer Center at the 2013 Gastrointestinal Cancers Symposium.
Read Article
New Antibody Targeting VEGF Receptor-2 Extends Survival in Advanced Gastric Cancer
By
Mark Knight
GI Cancers Symposium
February 2013, Vol 4, No 2
San Francisco, CA—Ramucirumab as a second-line therapy extended overall and progression-free survival in a phase 3 clinical trial of patients with metastatic gastric cancer, said Charles S. Fuchs, MD, MPH, Director of the Center for Gastrointestinal Cancer at Dana-Farber Cancer Institute, Boston, and Professor of Medicine at Harvard Medical School, at the 2013 Gastrointestinal Cancers Symposium.
Read Article
In First-Line Metastatic CRC, Outcomes Comparable for Panitumumab and Bevacizumab
By
Audrey Andrews
GI Cancers Symposium
February 2013, Vol 4, No 2
San Francisco, CA—A randomized phase 2 study that compared panitumumab (Vectibix) and bevacizumab (Avastin) in the first-line treatment of metastatic colorectal cancer (CRC) showed these drugs to be similar in terms of progression-free survival (PFS) and overall survival (OS) benefits.
Read Article
Nab-Paclitaxel Added to Gemcitabine Extends Survival in Patients with Metastatic Pancreatic Cancer
By
Mark Knight
GI Cancers Symposium
February 2013, Vol 4, No 2
When added to gemcitabine, weekly
nab
-paclitaxel improved survival in patients with advanced pancreatic cancer by nearly 2 months compared with gemcitabine alone, said Daniel D. Von Hoff, MD, FACP, Physician in Chief and Director of Translational Research, Translational Genomics Research Institute, Phoenix, regarding the results of a large international phase 3 clinical trial.
Read Article
Serum-Based Immunoassay May Detect Pancreatic Cancer Early
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—A serum-based enzyme immunoassay using the PAM4 antibody, combined with the serum marker CA19-9, detected stage I pancreatic cancer in nearly two thirds of patients analyzed in a study presented at the 2012 Gastrointestinal Cancers Symposium.
Read Article
Regorafenib Extends Survival in Advanced CRC
By
Caroline Helwick
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—The novel tyrosine kinase inhibitor (TKI) regorafenib, used as a single agent to treat treatment-refractory metastatic colorectal cancer (CRC), significantly improved survival and delayed disease progression in an international phase 3 trial presented at the 2012 Gastrointestinal Cancers Symposium.
Read Article
Promising Data for New DNA Stool Testing, at Low Cost
GI Cancers Symposium
February 2012, Vol 3, No 1
>San Francisco, CA—The “eradication” of colorectal cancer (CRC) may be a step closer, based on promising data for stool DNA testing, said David A. Ahlquist, MD, Mayo Clinic, Rochester, MN, at the 2012 Gastrointestinal Cancers Symposium.
Read Article
Molecular Profiling for Stage II Colon Cancer
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—Approximately 80% of patients with stage II colon cancer will be cured by surgery alone, but 20% will still relapse. Oncologists struggle with the question of which patients could benefit from adjuvant chemotherapy to reduce this risk, and which patients can be safely observed, without further treatment.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma